power to clearly detect genetic effects, most of which would be quite small individually (though substantial in combination). New and more efficient molecular technologies reduced the costs of genome-wide genotyping, and large-scale highly collaborative approaches—such as those conducted by the Psychiatric Genomics Consortium 4 ( http://www.med.unc.edu/pgc)—are now bearing fruit. These large-scale collaborative genomic studies have accelerated our knowledge of the molecular architecture of many psychiatric disorders to an unprecedented degree in the last decade 5. These studies have also enabled insights into the pleiotropy of genetic effects across disorders 5, which are clinically differentiated on the basis of patterns of symptomatology but which often share clinical features.
